Skip to main content

Table 3 Minimal clinically important difference thresholds for two anchor-based approaches

From: Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

 

10% difference in score range

Mean baseline difference between ECOG performance scores 0 vs 1 to 2

Total FACT-MM

16.4

13.5

FACT-G

10.8

7.8

FACT-TOI

8.4

11.0

MM Domain

5.6

5.8

  1. ECOG Eastern Cooperative Oncology Group, FACT-G Functional Assessment of Cancer Therapy – General, FACT-MM Functional Assessment of Cancer Therapy – Multiple Myeloma, MM multiple myeloma, TOI Trial Outcomes Index